New Oral Drug Zuranolone (Zurzuvae) for Postpartum Depression is Now Available
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
New Oral PPD Treatment Zuranolone Will Soon Hit the Market as Zurzuvae
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
FDA Approves Zuranolone for the Treatment of Postpartum Depression
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
More Data on Zuranolone for Postpartum Depression: When Will It Hit the Market?
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
Single Day CBT-Based Workshops for Mothers with Postpartum Depression
In this randomized controlled trial, a CBT-based workshop for women with PPD led to clinically meaningful reductions in depression and anxiety.
Recruiting for Research Study: Pregnenolone Neurosteroid for Menopausal Depression
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
New Research Study at the CWMH: A Novel Treatment for Menopausal Depression
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
In Subfertile Women Who Conceive With or Without Assistance, Low Risk of Postpartum Depression
Risk of PPD is low in women who successfully conceive.
Zuranolone for Postpartum Depression: Results from the SKYLARK Study
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
Essential Reads: Zuranolone for Postpartum Depression
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â